ALD

Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022

Retrieved on: 
Tuesday, November 8, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Food, Plasma, Prescription, Adrenoleukodystrophy, VLCFA, TZD, ALD, Growth, Fibrosis, FDA, Patient, Association, Company, MD, Biomarker, Serono, NASH, Merck Serono, AMN, ODD, Clinical trial, Orphan, Institute of Liver and Biliary Sciences, American Association, ADPKD, Disease, Fatty liver disease, POC, IPF, American Association for the Study of Liver Diseases, Non-alcoholic fatty liver disease, USD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Histology, Merck, Autosomal dominant polycystic kidney disease, Magnetic resonance imaging, Human, JPY, Degenerative disease, Edema, Pioglitazone, EUR, IRIS, Safety, AASLD, Male, Pharmacokinetics, Type 2 diabetes, Pharmaceutical industry, Euronext, Imeglimin

The royalty stream from TWYMEEGs growth is poised to deliver significant value to Poxel, noted Thomas Kuhn, Chief Executive Officer of Poxel.

Key Points: 
  • The royalty stream from TWYMEEGs growth is poised to deliver significant value to Poxel, noted Thomas Kuhn, Chief Executive Officer of Poxel.
  • This is an important milestone for Poxel, but also more broadly for NASH, for which there is still no approved treatment.
  • Based on these results, we are prioritizing PXL065 in NASH and are actively looking for a partner to advance its development.
  • Third Quarter and Nine Months Ended September 30, 2022 Cash and Revenue
    As of September 30, 2022, total cash and cash equivalents were EUR 17.1 million (USD 16.6 million), as compared to EUR 16.1 million at June 30, 2022.

Poxel Announces Upcoming Participation at the Jefferies London Healthcare Conference

Retrieved on: 
Monday, November 7, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, ALD, Euronext Paris, Company, Degenerative disease, NASH, ADPKD, Fatty liver disease, Forward-looking statement, Adenosine, AMPK, Adrenoleukodystrophy, Partnership, Conference, Fine chemical, Euronext, Imeglimin

POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the Jefferies London Healthcare Conference, to be held in London from Tuesday, November 15 to Thursday, November 17, 2022.

Key Points: 
  • POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the Jefferies London Healthcare Conference, to be held in London from Tuesday, November 15 to Thursday, November 17, 2022.
  • Members of the Poxel management team will be available for one-on-one meetings with investors.
  • Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders.
  • Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

ALD: Third quarter 2022 Results

Retrieved on: 
Monday, November 7, 2022
Face, Central bank, Professional, Ministry, Growth, LeasePlan, EUR, Ministry of Finance (Chile), Income, Total, Legislation, Regulatory News Service, Central Bank of Russia, NET, EV, UCS, Electric vehicle, OF, Acquisition, ALD, Depreciation, Security (finance), Film, Jet fuel, Renewable energy, Risk management, Holding company, Real estate, Semiconductor, Euro, FFM, Lease

Against this background and in view of the outstanding results recorded in 9M 2022, ALD is upgrading its guidance for the full year 2022 as follows:

Key Points: 
  • Against this background and in view of the outstanding results recorded in 9M 2022, ALD is upgrading its guidance for the full year 2022 as follows:
    ALD expects the used car market to remain strong at least until the end of the year.
  • Notwithstanding, the reduction in depreciation costs [1] recorded since H1 2022 (increasing the Leasing contract margin) anticipated part of expected future UCS results.
  • UCS result reached EUR 3,014 per unit in Q3 2022, down from EUR 3,330 per unit in Q2 2022.
  • ALD sold 198 thousand units [9] in 9M 2022, of which 63 thousand units in Q3 2022, vs 247 thousand in 9M 2021.

Ria Health Awarded $2 Million Grant from National Institutes of Health (NIH) for Clinical Trial

Retrieved on: 
Friday, November 4, 2022
Blood pressure, Randomized controlled trial, Alcoholism, Mortality, Health care, CDC, Stanford University, Death, Woman, FDA, American Association for the Study of Liver Diseases, National, Drinking, COVID-19, Institute of Liver and Biliary Sciences, Transaminase, Liver failure, Center, CEO, Research, Program, Physician, MAT, Clinical trial, Liver disease, Korea Disease Control and Prevention Agency, Prevalence, Partnership, AUD, Cirrhosis, ALD, Technology, American Association, NIH, Self-destructive behavior, Association, Patient, News, MPH, National Institute on Alcohol Abuse and Alcoholism, Pharmaceutical industry, Doctor of Philosophy, Medicine

WASHINGTON, Nov. 4, 2022 /PRNewswire/ -- Ria Health, a leading telehealth provider specializing in Alcohol Use Disorder treatment (AUD), today announced it has received a $2 million grant from the National Institutes of Health (NIH) for a clinical trial assessing its medically assisted treatment program's effectiveness—The Ria Health Program—in decreasing problem drinking and resulting markers related to liver disease. News of the trial, conducted in partnership with Stanford University, was announced at The Liver Meeting, the leading national conference for hepatology, hosted by the American Association for the Study of Liver Diseases.

Key Points: 
  • Ria Health, a telehealth provider for Alcohol Use Disorder received a $2M grant from the National Institutes of Health.
  • "It will support a randomized controlled trial evaluation of Ria Health's telehealth intervention to increase screening and treatment for alcohol use disorder."
  • "Research reported in this publication was supported by the National Institute On Alcohol Abuse And Alcoholism of the National Institutes of Health under Award Number R44AA030702.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."

ALD Launches First-to-Market Balancing Chip for Supercapacitors Rated at 3.00 Volts or Higher Preventing Overvoltage Failures

Retrieved on: 
Monday, October 31, 2022
MOSFET, Leadership, SAB, IDS, Temperature, EPAD, Cell, Technology, VGS, CMOS, VIN, ALD, Electronic component

SUNNYVALE, Calif., Oct. 31, 2022 /PRNewswire-PRWeb/ -- Advanced Linear Devices Inc. (ALD), a design innovator in analog semiconductors, today announced an addition to the quad family of Supercapacitor Auto Balancing (SAB™) MOSFETS. The precision MOSFET array offers a simple, economical and effective method to balance and regulate supercapacitors rated at a higher voltage. The chip is built using ALD EPAD® proven production technology. The ALD810030 stabilizes supercapacitors that can be used in a wide variety of applications, such as actuators, telematics, solar panels, emergency lighting, security equipment, barcode scanners, advanced metering boxes and battery backup systems.

Key Points: 
  • SUNNYVALE, Calif., Oct. 31, 2022 /PRNewswire-PRWeb/ -- Advanced Linear Devices Inc. (ALD), a design innovator in analog semiconductors, today announced an addition to the quad family of Supercapacitor Auto Balancing (SAB) MOSFETS.
  • The precision MOSFET array offers a simple, economical and effective method to balance and regulate supercapacitors rated at a higher voltage.
  • The chip is built using ALD EPAD proven production technology.
  • "Once again, ALD's technology leadership has created a product that is always on for balancing larger supercapacitors that uses virtually no power," said Robert Chao, president and founder of ALD.

Forge Nano Appoints Don Kaiser as COO for Continued Advancement of Battery Technology Market

Retrieved on: 
Tuesday, October 18, 2022
Lithium, Growth, Aptiv, Atomic, Lithium-ion battery, Atomic layer deposition, Technology, Company, Industry, CEO, Safety, Research in lithium-ion batteries, GLOBE, ALD, A123 Systems, Engineering

He joins Forge Nano from previous roles at Aptiv and A123 Systems with vast experience that includes executive-level PE assignments for over 20 sites worldwide.

Key Points: 
  • He joins Forge Nano from previous roles at Aptiv and A123 Systems with vast experience that includes executive-level PE assignments for over 20 sites worldwide.
  • Forge Nano will leverage Don's expertise in the Lithium Ion Battery market to build the infrastructure needed to bring Forge Nano's next-gen Atomic Armor technology to the market.
  • "Forge Nano will capitalize on Don's experience building A123 battery factories globally and a long history in operational excellence," said Paul Lichty, CEO, Forge Nano.
  • Forge Nano is a global leader in surface engineering and precision nano-coating technology, using Atomic Layer Deposition (ALD).

Atomic Layer Deposition Global Market Report 2022: Rise in Demand for Solar Devices Drives Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, October 17, 2022
Cosmetics, Retail, PV, CAGR, ASM International, Technology, Region, Lam Research, Hitachi, Tokyo Electron, Marketing, Industry, US, Application, Wonik Yi, ALD, Cosmetics, Engineering, Renewable energy, Aluminium, Retail, 3D printing, Lithium

As cosmetics witness a higher demand, demand for atomic layer deposition increase, particularly as people try to move to nonpetroleum-based products.

Key Points: 
  • As cosmetics witness a higher demand, demand for atomic layer deposition increase, particularly as people try to move to nonpetroleum-based products.
  • A strong focus on personal grooming and good hygiene is propelling the cosmetics market growth, which in turn, is driving the global atomic layer deposition market growth.
  • Atomic layer deposition acts as a nonpetroleum product alternative for the cosmetics and personal care industry, which is expected to drive the global atomic layer deposition market growth.
  • Hence, the rise in demand for solar devices is expected to drive the target market growth over the forecast period.

Li-Ion Battery Cathode Performance and Cost Improvements Are Targeted by Forge Nano and Sylvatex in a New Collaboration

Retrieved on: 
Thursday, October 13, 2022
Lithium, Adoption, CA, Particle, SVX, CAMS, Volkswagen, Original equipment manufacturer, Air Liquide, Carbon, Atomic layer deposition, Technology, Cathode, Company, EV, Water, Safety, GLOBE, ALD, Engineering, Sintering, Electric battery

The collaboration facilitates the delivery of next-generation Li-ion battery CAM at a commercial scale in North America.

Key Points: 
  • The collaboration facilitates the delivery of next-generation Li-ion battery CAM at a commercial scale in North America.
  • Using less energy and water will overcome the problems of cathode manufacturing that limit battery manufacturers and OEMs today."
  • Sylvatex (SVX) is transitioning the world's energy systems through foundational manufacturing improvements impacting our zero-emission electric future and grid storage.
  • The Company has developed and is commercializing a lithium-ion battery cathode production technology that uses a sustainable, waterless manufacturing process.

Poxel Announces Upcoming Presentation at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference

Retrieved on: 
Thursday, October 13, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Type 2 diabetes, Time, Disease, Triglyceride, Cholesterol, Investor, Conference, Euronext Paris, Lists of diseases, Corporation, Inflammation, ADPKD, Partnership, Liver cancer, Degenerative disease, NASH, Company, Obesity, CEO, Cirrhosis, CEST, AMPK, Liver, Non-alcoholic fatty liver disease, Fibrosis, Forward-looking statement, ALD, Liver failure, Fatty liver disease, Adrenoleukodystrophy, Adenosine, Pharmaceutical industry, Audit, Euronext, Imeglimin

POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it is presenting at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference on Monday, October 17th, 2022 at 10:00 am ET (4:00 pm CEST).

Key Points: 
  • POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it is presenting at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference on Monday, October 17th, 2022 at 10:00 am ET (4:00 pm CEST).
  • Thomas Kuhn, CEO of Poxel, and other members of the Poxel management team will be available for one-on-one virtual meetings.
  • Typical risk factors for NASH include obesity, elevated levels of blood lipids (such as cholesterol and triglycerides) and type 2 diabetes.
  • Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders.

Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022

Retrieved on: 
Wednesday, October 12, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, ACSL4, Non-alcoholic fatty liver disease, Pioglitazone, Euronext Paris, ADPKD, Liver cancer, American Association, Association, Adrenoleukodystrophy, Biomarker, Adenosine, American Association for the Study of Liver Diseases, QD, Lists of diseases, Fibrosis, Inflammation, Company, Obesity, Bone, Degenerative disease, Cirrhosis, European Association for the Study of the Liver, ALD, Liver failure, FDA, Time, Risk, Deuterium, EASL, Edema, Weight gain, AASLD, Type 2 diabetes, Disease, Triglyceride, Cholesterol, Histology, Partnership, Human, National Disaster Management Authority (India), AMPK, Safety, MPC, Forward-looking statement, Fatty liver disease, Institute of Liver and Biliary Sciences, Pharmaceutical industry, Medical imaging, Copper, Euronext, Liver, Imeglimin, Patient

The study also assessed the effects of PXL065 on liver histology and other metabolic and non-metabolic biomarkers.

Key Points: 
  • The study also assessed the effects of PXL065 on liver histology and other metabolic and non-metabolic biomarkers.
  • Analysis of histologic changes was based on paired liver biopsies in PXL065 vs. placebo-treated NASH patients before and after the 36-week treatment period.
  • Across all PXL065 treatment arms (pooled data), 39% of patients had fibrosis improvement by 1 stage without worsening NASH (%) vs. 17% with placebo.
  • For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1).